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Here we have collected evidence suggesting that chronic changes in the NO homeostasis and the rise of reactive oxygen species
bioavailability can contribute to cell dysfunction in Leber’s hereditary optic neuropathy (LHON) patients.We report that peripheral
blood mononuclear cells (PBMCs), derived from a female LHON patient with bilateral reduced vision and carrying the pathogenic
mutation 11778/ND4, display increased levels of reactive oxygen species (ROS) and reactive nitrogen species (RNS), as revealed
by flow cytometry, fluorometric measurements of nitrite/nitrate, and 3-nitrotyrosine immunodetection. Moreover, viability assays
with the tetrazolium dye MTT showed that lymphoblasts from the same patient are more sensitive to prolonged NO exposure,
leading to cell death. Taken together these findings suggest that oxidative and nitrosative stress cooperatively play an important
role in driving LHON pathology when excess NO remains available over time in the cell environment.
1. Introduction
Leber’s hereditary optic neuropathy (LHON) is a mito-
chondrial disorder leading to severe visual impairment, due
to retinal ganglion cells (RGCs) death and atrophy with
demyelination of the optic nerve [1]. The primary cause of
the disease is a mitochondrial genome (mtDNA) mutation
leading to a single amino acid substitution in one of themito-
chondrially encoded subunits of NADH:ubiquinone oxidore-
ductase, complex I of the electron transport chain (ETC).
The most common mutations are at positions 11778/ND4,
3460/ND1, and 14484/ND6 [2, 3].
LHON pathology generally occurs in the second or third
decade of life and affects predominantly males [4]. The only
clinically relevant phenotype in most of the patients is RGCs
loss, seldom accompanied by other complicating neurolog-
ical disorders, such as dystonia, multiple sclerosis- (MS-)
like illness parkinsonism, cerebellar ataxia, and myoclonus
[5], pointing to a diffused mitochondrial energetic failure.
Interestingly, a higher risk of developing MS in women
with clinically established LHON has been reported [6–
8]. Rarely other phenotypes have been described, such as
chronic renal failure [9, 10], involving as common feature
tissues/cells that are exquisitely energy dependent and require
adequate supply of reducing substrates and O
2
to sustain
mitochondrial adenosine-5󸀠-triphosphate (ATP) production.
All LHON mutations induce an impairment of mito-
chondrial function. A decline in complex I-sustained cell
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respiration and ATP production has been reported in assays
performed on isolated mitochondria derived from muscle,
Epstein-Barr Virus- (EBV-) transformed leukocytes, periph-
eral blood mononuclear cells (PBMCs), and cybrids [11–
15]. Based on these specific defects, experiments carried out
on patient’s tissues and cell models of the disease showed
an overproduction of reactive oxygen species (ROS) and
an increased propensity to apoptotic cell death [16]. Nev-
ertheless, LHON cells seem to be able to cope with the
ETC dysfunction, maintaining apparently a normal growth
and total cellular ATP level, yet being more vulnerable to
metabolic/oxidative stress or other stressful conditions [2, 17].
Consistently, a recently developedmousemodel revealed,
together with some of the key histopathological features
typically observed in LHONpatients, the decrease of complex
I activity, respiratory defects, and the increase in ROS levels,
but no reduction in ATP synthesis, pointing to oxidative
stress as the major driver of the pathology [18]. On these
bases, most of therapeutic approaches to LHON, and gen-
erally to mitochondrial disorders, currently rely on the
use of mitochondrial substrates, together with redox active
effectors and free radical scavengers. Idebenone, curcumin,
and vitamins C and E as well as other antioxidant compounds
have been used separately or combined in “cocktails” cus-
tomized for the individual patients [19, 20], all treatments
unfortunately with limited success.
Under severe pathological conditions, such as inflamma-
tion or sepsis, a disruption of the homeostatic control of oxy-
gen supply and utilization has been observed, accompanied
by ROS formation, together with an imbalance of nitric oxide
(NO) production and breakdown. Nitric oxide produced
either enzymatically by nitric oxide synthases (NOSs) [21]
or directly via the reduction of bulk nitrite at low pH [22]
is a fundamental second messenger involved in a number
of pathophysiological processes [23], inducing detrimental
or cytoprotective effects depending on its concentration and
localization [24]. Importantly, NO regulates mitochondrial
respiration by reversibly binding to cytochrome 𝑐 oxidase
and limiting O
2
consumption, while extending O
2
gradients
in tissues [25, 26]. Such inhibition is more effective in
actively respiring cells and at low oxygen concentration [27–
29]. Under conditions associated with increased ROS levels,
NO participates in reactions with other reactive species to
generate secondary products that can impair mitochondrial
function. Particularly, the reaction of NO and superoxide
anion (O
2
−∙), leading to the formation of toxic peroxynitrite
(ONOO−), is very rapid (diffusion limited) and known to
induce macromolecular damage, including nitration and
inactivation of mitochondrial proteins [30].
Although many biochemical aspects of LHON have been
elucidated, the role of NO in the LHON disease has not been
investigated yet. Interestingly, an increased immunoreactivity
for inducible nitric oxide synthase (iNOS) has been detected
in macrophages and in the microglia of demyelinated lesions
in the brain white matter of a LHON female patient, suggest-
ing an early immunological mechanism in addition to the
primary degeneration of the optic nerve [31]. In this patient,
administration of corticosteroids improved visual and neu-
rological function. This observation suggests that increased
NO levels, as those produced by iNOS, in combination with
ROS overproduction can result into mitochondrial defects,
eventually triggering severe cell dysfunctions.
Here, we tested this hypothesis on PBMCs and lym-
phoblasts derived from a female LHON patient with bilateral
reduced vision and immunological disorders. We found
that the cells, although carrying the pathogenic mutation
11778/ND4, are still endowed with a suitable bioenergetic
apparatus, producing ATP, thus well compensating complex
I mutation. However, lymphoblasts proved to be more sus-
ceptible to NO toxicity, suggesting that the mitochondrial
genetic defect, via the enhancement of the basal ROS levels,
potentiates the formation of secondary reactive nitrogen
species (RNS), particularly ONOO−, leading to reduced cell
viability.
2. Materials and Methods
2.1. Chemicals. RPMI-1640medium, fetal bovine serum (FBS),
and nonessentialamino acid solutionwere fromSigma-Aldrich
and Invitrogen Life Technologies (GIBCO). Thiazolyl blue
tetrazolium bromide (MTT) was from Sigma-Aldrich and
(Z)-1-[-2-(aminoethyl)-N-(2-ammonioethyl)amino]diazen-
1-ium-1,2-diolate (DETA-NONOate) was purchased from
Cayman Chemicals.
2.2. Case Report. The proband is 34-year-old woman with
a previous diagnosis of autoimmune thyroiditis. When she
was 28 years old, she suffered a sudden and painful loss
of vision in OS and after two weeks in OD, accompanied
by xerophthalmia. Visual field showed retinal sensibility
reduction, especially at superior areas, whereas fluoroan-
giography was normal. She was treated with high doses of
corticosteroids and intravenous immunoglobulins without
benefits. Brain MRI scan was unremarkable. After 4 months,
plasmapheresis was performed with little improvement, so
it was decided to start cyclophosphamide treatment. This
treatment was carried on for 6 months without any benefit.
In the meantime, after a femur fracture due to an accidental
fall, a severe osteoporosis was diagnosed. After one year from
the visual loss, a workout for autoimmune disorders gave
positive ANA (speckled pattern, 1 : 160) and the presence
of anti-Ro/SSA. Cytochemical, bacteriological, viral, and
immunoelectrophoretic analyses on cerebrospinal fluid were
normal.
Brainstem auditory evoked responses, along with motor
and somatosensory evoked potentials, were normal, while
visual evoked potentials could not be performed due to
bilateral visual loss. A new brain and orbital and spinal
cord MRI scan showed bilateral callosal, periventricular, and
paratrigonal white matter symmetric hyperintensities on T2-
weighted images without contrast enhancement on T1. No
alterations were found at the level of the spinal cord and
optic nerves. On admission to our neurological division,
bilateral visual acuity was 1/10. We excluded neoplastic or
paraneoplastic processes by full-body CT scan and screening
for antibodies associated with paraneoplastic syndromes.
The infectious aetiology was also discarded after negative
hepatitis B and hepatitis C virus, HIV, EBV, cytomegalovirus
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serology, and tuberculin skin test. Neuromyelitis optica,
carential, metabolic, and endocrinological disorders were
also excluded. The standard genetic screening for LHON
disease showed the presence of 11778/ND4 mutation. She
began ubidecarenone therapy (600mg/day) without any sub-
jective or measurable improvement of visual acuity. After
twomonths she developedEscherichia coli pyelonephritis and
chronic tubulointerstitial nephritis was diagnosed. After one
year and a half from the visual loss, the patient presented a
bilateral visual acuity worsening with a severe headache and
hypoesthesia at four limbs. A brain MRI showed a massive
extension of bilateral paratrigonal white matter lesions with
an involvement of bilateral occipital subcortical white matter
and increased signal intensity on T2-weighted images of
optical radiations and retrochiasmatic optic tracts. After one
month, brain MRI with contrast and diffusion weighted
imaging was repeated showing an additional enlargement of
bilateral occipital lesionswith positivity inDWI sequence and
a circled enhancement. Therefore she was admitted again to
our division and a hemogasanalysis proved a severemetabolic
acidosis (pH 7.14, pCO
2
= 13mmHg, pO
2
= 145mmHg,
sO
2
= 98.5%, HCO
3
− = 4.40mmol/L, BE = −22.40mmol/L,
and BEecf = −24.60). Blood lactate measurements showed
an abnormal increase during exercise (at rest 13.69mg/dL;
after 5-minute exercise 48.13mg/dL; after 10-minute exercise
65.53mg/dL; after 15-minute exercise 85.57mg/dL; 15minutes
after the end of exercise 59.28mg/dL; and normal value 4.5–
19.8). Blood analysis showed a renal injury associated with
nephrocalcinosis diagnosed by ultrasonography andCT scan.
During the hospitalization the medical care focused on the
improvement of electrolyte balance and renal injury until
values normalization. Simultaneously, by brain MRI scan,
we appreciated a clear reduction of white matter lesions and
contrast enhancement absence.
2.3. Peripheral Blood Mononuclear Cells (PBMCs) Isolation.
Blood samples were obtained from the case report and from
three matched (age, sex, and geographical origin) healthy
controls. The local Institutional Review Board approved the
study and all participating subjects gave written informed
consent.
PBMCs were obtained by density centrifugation over
Ficoll-Hypaque according to standard procedures. Genomic
DNA was extracted from PBMCs using a commercial kit
(QIAamp DNA Mini Kit, Qiagen). Purified PBMCs (5 × 104
cells/well) were seeded in 96-flat well plates and cultured
in 200𝜇L/well RPMI-1640 medium, supplemented with 20%
FBS (HyClone), 2mML-glutamine, 100U/mL penicillin, and
100 𝜇g/mL streptomycin.
2.4. Preparation andCultures of Lymphoblast Cell Lines. Lym-
phoblast cell lines were established from peripheral blood
PBMCs of the patient and the three healthy controls by EBV
infection. The mutational analysis of the patient mtDNA was
performed by PCR, restriction analysis, and electrophoresis
and confirmed by sequencing (Sangermethod). Both PBMCs
and lymphoblast cell lines derived from the LHON patient
and controls were grown in RPMI-1640 medium supple-
mented with 20% (v/v) heat-inactivated fetal bovine serum
(FBS), 2mM L-glutamine, 100U/mL penicillin, 100 𝜇g/mL
streptomycin, and 1X nonessential amino acids. Cells were
cultured in 25 cm2 or 75 cm2 flasks or in multiwell plates and
incubated at 37∘C under standard conditions [5% CO
2
; 95%
relative humidity]. Viable-cell counting was carried out using
the Trypan blue dye exclusion test (Sigma-Aldrich).
2.5. Cell Respiration. Oxygen consumption in intact PBMCs
derived from the LHON patient and controls was mea-
sured using a high resolution respirometer (2k-Oxygraph,
OROBOROS Instruments). Data acquisition and analysis
were carried out using the software Datalab (OROBOROS
Instruments). Control and LHON PBMCs were collected,
washedwith sterile phosphate buffered saline (PBS), counted,
and suspended in DMEM containing 1 g/L glucose. Cells,
at a final density ranging from 7 to 9 × 106 cells/mL, were
incubated in the 2k-Oxygraph chambers at 37∘C for 30min
to allow temperature and pH equilibration. Respiration was
evaluated under basal metabolic conditions, thus sustained
by endogenous substrates. After recording an oxygen con-
sumption rate (OCR) baseline, 4𝜇M antimycin A (AA) was
added to the chamber in order to inhibit cytochrome 𝑐
reductase (complex III) and stop mitochondrial respiration.
Data were recorded at sampling intervals of 2 s.
2.6. Determination of ATP Levels. Cellular concentration of
ATP was measured by chemiluminescence, under stationary
conditions. Cells were incubated overnight in antibiotic/FBS-
free DMEM medium. Steady-state ATP levels were mea-
sured in LHON and control PBMCs (3 × 105 cells/mL) 4 h
after resuspending the cells in PBS containing L-glutamine
(2mM), in the presence of glucose (2 g/L) or its absence to
stimulate OXPHOS; when necessary, oligomycin (2.5 𝜇g/mL)
was added over the last 1.5 h of incubation. Synthesized ATP
was measured using the ATPlite 1step kit (PerkinElmer) in
a luminometer (VICTOR Multilabel Counter, PerkinElmer,
USA) equipped with 96-well plates.
2.7. Reactive Oxygen Species (ROS) Quantification by Flow
Cytometry. To measure the intracellular ROS concentra-
tion, the fluorescent probe 2󸀠,7󸀠-dichlorofluorescein diac-
etate (DCFDA, Sigma-Aldrich) was used. PBMCs from the
LHON patient and controls were incubated for 30min at
37∘C in the dark in RPMI-1640 medium containing 10 𝜇M
DCFDA. Afterwards, cells were washed twice with Hank’s
Buffered Salt Solution (HBSS) supplemented with calcium
andmagnesium, as suggested by the manufacturer, collected,
and analysed immediately by flow cytometry (BD Accuri
C6); ROS levels were estimated from the mean fluorescence
intensity.The green fluorescence was measured using the FL-
1 setting (log mode) after having gated out cell debris. In each
experiment 10.000 events were recorded.
2.8. 3-Nitrotyrosine Level Detection. The content in 3-nitro-
tyrosine (3-NT) modified proteins was used as marker of
protein damage by ONOO−. The intracellular 3-NT levels
were assessed colorimetrically using a competitive ELISA kit
(Abcam). For each independent experiment a standard curve
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was generatedwith the provided 3-NT standard and the 3-NT
content quantified.
2.9. Nitrate/Nitrite (NOx) Determination. NOx concentration
in cell supernatants was determined fluorimetrically using
Fluorimetric Assay Kit (Cayman Chemical), 48 h after cells
seeding.
2.10. Cell Viability Assay. After 48 h incubation in presence or
absence of the NO donor DETA-NONOate, the viability of
lymphoblast cells was assessed using the MTT [-3(4,5-dim-
ethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] reduc-
tion assay as described in [32]. Briefly, cells (2 × 105/mL) were
seeded in a 96-well plate and incubated for 48 h at 37∘C in
the presence of increasing DETA-NONOate concentrations
(0.01–0.5mM) in a final volume of 100 𝜇L/well. Having a
half-life of 20 h at 37∘C, the NO donor was readded after
24 h. At the end of the 48 h incubation, 10 𝜇L of MTT
solution (5mg/mL) was added to each well, followed by
4 h incubation at 37∘C. Afterwards, in order to dissolve
the dark-coloured formazan crystals produced by reduction
of the MTT tetrazolium salt, cells were incubated at 37∘C
overnight with 100 𝜇L of 10% sodium dodecyl sulphate (SDS)
in 0.01M HCl. The optical density of reduced MTT was
measured at 570 nm with a reference wavelength at 690 nm
using Appliskan Microplate Reader (Thermo Scientific). The
experiments were carried out in triplicate.
2.11. Statistical Analysis. Data are reported as mean ± SEM of
at least three independent experiments and significance (𝑃)
was determined using Student’s 𝑡-test. 𝑃 values ≤ 0.05 were
considered significant.
3. Results
3.1. Mitochondrial Function in LHON Patient PBMCs. RGCs,
brain, and kidneys, the most affected sites in the LHON
patient, are all high-energy demanding, so they rely more
on OXPHOS ATP. Importantly, PBMCs have a metabolism
mainly sustained by OXPHOS [33, 34] and therefore repre-
sent a goodmodel to be investigated in the present study. Fig-
ure 1(a) shows a typical oxygen consumption trace acquired
with intact PBMCs. The oxygen consumption was sustained
by endogenous substrates and relied almost completely on
mitochondria, as it was almost completely inhibited by
antimycin A, a specific inhibitor of cytochrome 𝑐 reductase.
After normalization to the protein content, we found the O
2
consumption rate (≈50 pmolO
2
s−1mg−1) to be very similar
in both LHON and control cells.
In agreement with these data, no significant differences
in the steady-state concentration of ATP were observed in
control and patient PBMCs. ATP levels were evaluated either
in the absence or in the presence of glucose to sustain
glycolysis and using oligomycin to inhibit OXPHOS activity.
When glucose was present (Figure 1(b)), both LHON and
control cells displayed a similar ATP content (ATPTOTAL ≈
6 𝜇gATP/mg total protein), and oligomycin inhibition of
OXPHOS was found poorly effective in control and LHON
PBMCs, suggesting that both cell types possess an effi-
cient glucose-dependent glycolytic compensation (Warburg
effect). Without glucose (Figure 1(c)), both LHON and
control cells showed ∼20% decrease in the ATP content,
whose concentration dropped dramatically in the presence
of oligomycin. Under the latter conditions, the glycolytic
contribution is minimal and the difference between the ATP
measured in the presence and absence of oligomycin (ΔATP)
is indicative of the ATP generated byOXPHOS (ATPOXPHOS).
The ATPOXPHOS/ATPTOTAL ratio (Figure 1(d)) is very similar
in LHON and control cells, indicating that the mutation does
not affect OXPHOS efficiency.
Taken together, these results suggest that, over and above
a bioenergetic deficit imputable to complex I mutation, other
molecular mechanisms contribute to the clinical onset of
LHON and its progress that we hypothesize to be also
related to increased cell levels of reactive oxygen and nitrogen
species.
3.2. Increased Level of ROS, 3-Nitrotyrosine, and Nitrite in
PBMCs. In order to investigate whether the PBMCs derived
from the LHON patient displayed increased oxidative/
nitrosative stress levels, we measured the amount of ROS
and 3-NT under basal conditions. The latter is an important
marker of RNS, including ONOO−. We found that LHON
PBMCs display a significant 1.4-fold increase in ROS produc-
tion compared to controls (Figure 2(a)). Consistently, LHON
PBMCs displayed a higher concentration of 3-NT, suggesting
a role of NO chemistry in cellular stress (Figure 2(b)).
To assess the basal NO level in LHON, we measured the
concentration of nitrite/nitrate, the oxidation products of
NO. Interestingly we found that the nitrite/nitrate levels
(Figure 2(c)) tend to increase compared to controls, although
the reported variation did not reach statistical significance.
Owing to a limited availability of biological samples (cells
from patient) and in order to obtain larger amounts of start-
ing material, EBV-transformed lymphoblasts were used for
further cell biochemical analysis. The bioenergetic behaviour
of primary and transformed cells was very similar, with
the two cell types displaying superimposable mitochondrial
parameters (data not shown).
3.3. DETA-NONOate Decreases LHON Lymphoblasts Viabil-
ity. A chronic increase in NO levels was artificially mim-
icked using the NO donor DETA-NONOate (DETA-NO).
Cell viability was examined in both LHON and control
lymphoblasts after 48 h incubation with different amounts
of the NO releaser. As a regulator of cell proliferation, NO
can either enhance or inhibit cell growth depending on
its concentration. Figure 3 shows that at 10 𝜇M DETA-NO
no cytotoxicity was associated with NO exposure. Higher
concentrations of DETA-NO affected cell viability propor-
tionally to the amount added. However, the decline in cell
viability was significantly larger in LHON than in control
cells: at 0.1 and 0.5mM DETA-NO, the residual viability
of LHON cells was 35% and 15%, respectively, while in
control cells it was, respectively, 75% and 35%. Trypan blue
exclusion assays, carried out under comparable experimental
conditions, indicated a similar cellular behaviour (data not
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Figure 1: Bioenergetic properties of 11778/ND4 mutated PBMCs. (a) Representative cell O
2
consumption measurements. Black line: O
2
concentration trace; red line: O
2
consumption rate. After recording basal respiration, 4 𝜇M antimycin A (AA) was added. (b) Cellular ATP
levels measured in the presence of glucose with and without oligomycin. (c) Cellular ATP levels measured in the absence of glucose with and
without oligomycin. (d) Fractional ATP expressed as the ratio between ATPOXPHOS and ATPTOTAL. ATPOXPHOS was obtained from ΔATP
(c) and ATPTOTAL was measured in the presence of glucose without oligomycin (b). Data (mean ± SEM) were collected in three triplicate
experiments on cells derived from the LHON patient and the three healthy controls.
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Figure 2: Oxidative and nitrosative stress is increased in 11778/ND4 mutated PBMCs. (a) Intracellular ROS levels were measured using the
DCFDA dye. (b)The 3-NT content was determined by competitive ELISA and normalized to total protein. (c) Concentration of NOx (nitrite
and nitrate) in the cell supernatant as normalized to total protein. Data (mean± SEM) collected in three duplicate experiments on cells derived
from the LHON patient and the three healthy controls. Values are considered significant when 𝑃 < 0.05: ∗𝑃 ≤ 0.05; Ns: not significant.
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Figure 3: NO impairs the viability of 11778/ND4 mutated lym-
phoblasts. The cells derived from the LHON patient and the three
healthy controls were treated with various concentrations of DETA-
NONOate for 48 h and their viability was assessed using the MTT
assay. Data are shown as the percentage of cell viability measured
in the absence of the NO releaser. Data acquired in three triplicate
experiments are expressed as mean ± SEM. Values are considered
significant when 𝑃 < 0.05: ∗𝑃 ≤ 0.05; ∗∗𝑃 ≤ 0.01.
shown), showing that LHON cells are more susceptible to
nitrosative stress than control cells.
4. Discussion
LHON is characterized by a low penetrance, as most indi-
viduals carrying mtDNA mutations remain asymptomatic,
with a limited subset of them expressing the disease. Age
and gender are the most important risk factors, with approx-
imately 30–50% of males and 10–20% of female LHON
mutation carriers becoming symptomatic at a median age of
19 years (range 5–56 years) [35]. Indeed, genetic, epigenetic,
and environmental factors all contribute to the onset and
evolution of the disease [36]. Complex I mutation, the
primary etiologic cause of LHON, despite being a necessary
determinant of the pathology, is not sufficient to induce
the clinical expression of the disease so that a convincing
explanation for the pathogenesis of this disorder is still under
debate. The impairment of bioenergetics parameters, such
as cell respiration and ATP production, has been found
absolutely modest both in patient’s tissues and in cell models
of the disease. On the contrary, a marked overproduction
of ROS has been reported, together with a low capability
of the cellular antioxidant machinery to maintain the redox
homeostasis.
LHON cybrid models have shown lower levels of glu-
tathione peroxidase, glutathione reductase, andMn-superox-
ide dismutase (MnSOD) or total glutathione, compared to
controls [37, 38], particularly after cell treatment to enhance
their OXPHOS dependency. These observations strongly
support the idea that the genetic alteration of complex I,
over and above the simple action on primary mitochondrial
parameters, induces an alteration of the cell redox-signalling
and homeostasis. Interestingly, in a cybrid model carry-
ing the G11778A/ND4 mutation, it has been observed that
mitochondrial overexpression of MnSOD induces a decrease
in superoxide levels and enhances cell survival [39]. While
chronic oxidative stress has been shown to play an important
role in the onset of the disease, the role of NO and related
reactive species remained unexplored. Together with CO and
H
2
S, NO forms the gasotransmitter triad acting as a redox-
signalling regulator of several physiological functions, the
mitochondrial one included [40]. NO, particularly at low
concentrations, protects against cell death [41–44], whereas
in the presence of superoxide it becomes toxic by forming
ONOO− [30]. It should be kept in mind, however, that, even
in the absence of ONOO−, depending on the electron flux
level through the respiratory chain, that is, on the concen-
tration of mitochondrial ferrocytochrome 𝑐, and particularly
under low O
2
tension (hypoxia), inhibition of mitochondrial
complex IV by NO can be severe and persistent [29, 45, 46].
According to our results, LHON cells are apparently
more prone to such NO-dependent detrimental chemistry.
We present here the case of a female patient with a point
mutation at nucleotide position G11778A, who suffered from
both eyes’ visual loss and subsequently displayed markers for
autoimmune disorders, as well as white matter alterations
outside the visual system.
We show that PBMCs and lymphoblasts derived from
our patient are more susceptible not only to oxidative but
also to nitrosative stress. In these cells we found that,
under metabolic basal conditions and in the absence of
exogenous NO, the 3-NT levels are enhanced. This finding is
in agreement with prior studies carried out on optic nerve
and retinal histological specimens obtained from LHON
patients and on synaptosomes from a mouse model of the
disease that have evidenced increased levels of 3-NT [18, 47].
The higher basal 3-NT concentration suggests that LHON
cells produce larger amounts of nitrosating agents, such
as ONOO−. Consistently, we found that the concentration
of nitrite/nitrate, the oxidation products of NO, tends to
increase in patient cells, compared to controls. Increase
in nitrosative stress might be particularly likely when NO
overproduction takes place.
The current study reveals that chronic exposure to NO
in proband lymphoblasts carrying the 11778/ND4 mutation
determines a significant decrease in cell viability compared
to controls, suggesting that in this pathological state the NO
chemistry is more active. Interestingly, our patient has shown
an abnormal increase in lactate serum levels after exercise,
suggesting a limited mitochondrial reserve capacity. In terms
of energy metabolism, under basal conditions the patient
PBMCs are able to fully compensate complex I mutation
allowing an efficient mitochondrial function. We observed
that the ATP levels in LHON cells were not significantly
different from those ones of control cells, even when the
glycolytic system was restricted by glucose deprivation.
Both cell types were equally able to efficiently compensate
OXPHOS defects with glycolysis, as shown by abolishing the
contribution of ATPOXPHOS with oligomycin.
Mitochondrial ATP generation is crucial for cell func-
tion; therefore mitochondria have evolved several different
strategies to maintain it to face dysfunctions. Switching
to glycolysis is fundamental for cell survival during acute
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stress, although this pathway represents a much less efficient
mode of ATP production, resulting in an energy deficit and
acidosis over long periods, especially in those cells relying
on high-energy demand. Cells derived from LHON carriers,
having the mitochondrial mutation but not expressing the
disease, were shown to adopt different responses that allow
the maintenance of the respiratory function and ATP levels,
such as increasing the activity of the succinate-dependent
pathway or the mitochondrial mass [13, 48]. The bioen-
ergetic compensation observed in individuals affected by
LHON can be disrupted by various factors, such as the
frequently suggested nuclear modifying genes and environ-
mental triggers. Smoking and alcohol are both known to
decrease the mitochondrial reserve capacity [49–51] and
have been reported to play a role in the onset of LHON
disease [36] also contributing to its incomplete penetrance.
A loss of mitochondrial reserve capacity, as obtained by the
chronic exposure to NO, decreases the ability to respond
to endogenous secondary energetic stressors, such as ROS
and RNS, which we observed to be increased in the patient
PBMCs. All together these findings point to a novel role
played by RNS, particularly ONOO−, whose accumulation
in LHON cells appears to have a role in the pathology and
its pharmacological control may be important in the patients
[52].
5. Conclusions
In conclusion, we show that lymphoblasts derived from a
LHON patient carrying the 11788/ND4 mutation are more
susceptible to NO, suggesting that the exposure to high NO
concentrations could impair in vivo the ability to cope with
the oxidative stress caused by the genetic defect, thereby
driving the pathology. This unprecedented observation is
consistent with both LHON cell and animal models pointing
to oxidative stress and impairment of redox homeostasis as
important factors contributing to the onset and progression
of the disease. Further work is needed to extend these studies
to other LHON cells or tissues in order to better understand
the reciprocal role of ROS and RNS in this pathology and to
design new drugs and appropriate therapeutic approaches.
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